NewAmsterdam Pharma reports Q4 EPS ($2.15), consensus ($2.11)
The Fly

NewAmsterdam Pharma reports Q4 EPS ($2.15), consensus ($2.11)

Reports Q4 revenue $14.1M, consensus $13.01M. “2023 was a year of remarkable progress for NewAmsterdam, marked by consistent clinical execution and substantial corporate development. We reported multiple encouraging datasets and expanded our team with key hires, underscoring our commitment to revolutionizing patient outcomes, building a fully integrated company with the potential to deliver obicetrapib globally, if approved, and continue creating significant value for our shareholders,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam. “We enter 2024 in a position of strength, with multiple upcoming milestones and a healthy balance sheet to support our operations. In the near-term, we look forward to topline results from BROOKLYN and BROADWAY in the third and fourth quarters of 2024, respectively, which we expect will build on the promising datasets generated from our prior Phase 2 trials and support obicetrapib’s ability to positively impact key lipid and lipoprotein measurements associated with risk for cardiovascular disease.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on NAMS:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App